<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04162522</url>
  </required_header>
  <id_info>
    <org_study_id>19-5371</org_study_id>
    <nct_id>NCT04162522</nct_id>
  </id_info>
  <brief_title>Canadian Biomarker Integration Network for Depression (CAN-BIND) - Validation Study</brief_title>
  <official_title>Integrated Biological Markers for the Prediction of Treatment Response in Depression: Validation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Michael's Hospital, Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baycrest</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre for Addiction and Mental Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Queen's University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Ottawa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McGill University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dalhousie University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Simon Fraser University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a validation study that will replicate a completed study designed to assess
      biomarkers of treatment response to standard antidepressant treatment. The goal of this study
      is to integrate clinical, imaging, EEG, and molecular data across 8 sites to predict
      treatment outcome for patients experiencing a major depressive episode (MDE).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-site study to replicate a previous multi-site, multi-platform study completed
      by the Canadian Biomarker Integration Network in Depression (CAN-BIND). This study aims to
      validate the integrated array of markers of response and non-response to first line
      antidepressant treatments that were previously identified in the original aforementioned
      study. This will be accomplished through collection of clinical, neurophysiological, and
      molecular measures. This is not a study to evaluate efficacy of medications; medications in
      this study have been approved by Health Canada and are widely used for the treatment of MDD.

      In this study, individuals diagnosed with MDD in a current major depressive episode (MDE)
      will be treated with open-label escitalopram for 8 weeks. At week 8, participants will be
      assessed for treatment response (defined as a ≥50% reduction in Montgomery Asberg Depression
      Rating Scale score). Responders will continue on escitalopram for 8 more weeks.
      Non-responders will be given add-on brexpiprazole treatment, in addition to escitalopram, for
      8 weeks.

      Over the 16 weeks, pariticipants will attend 7 clinical visits where they will complete
      clinical assessments (clinician administered and self-report) and cognitive tests; provide
      blood, urine, and stool samples; undergo neuroimaging procedures (MRI and EEG); and provide
      speech samples. At the end of the study, modeling methods will be used to integrate data from
      these measures to determine the features that best predict treatment outcome.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 23, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Montgomery Asberg Depression Rating Scale (MADRS) scores from baseline</measure>
    <time_frame>Week 8, Week 16</time_frame>
    <description>Measured as clinical response, defined as a decrease in Montgomery Asberg Depression Rating Scale (MADRS) score at the Week 8 and Week 16 visits, by 50% or greater, from MADRS score at Baseline visit (i.e., lower MADRS scores = better outcome)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>escitalopram (10-20 mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants are given escitalopram for 8 weeks. At week 8, participants will be assessed and classified as &quot;responders&quot; or &quot;non-responders&quot;. Responders will continue on escitalopram until the study endpoint (16 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>brexpiprazole (0.5-2 mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At week 8, participants classified as &quot;non-responders&quot; will be given 8 weeks of brexpiprazole as add-on treatment to escitalopram.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>Participants are given escitalopram for 8 weeks. At week 8, those classified as responders will continue on escitalopram until the end of study.</description>
    <arm_group_label>escitalopram (10-20 mg)</arm_group_label>
    <other_name>Cipralex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brexpiprazole</intervention_name>
    <description>Participants who are classified as non-responders are given 8 weeks add-on brexpiprazole, in addition to escitalopram, for the remainder of the study.</description>
    <arm_group_label>brexpiprazole (0.5-2 mg)</arm_group_label>
    <other_name>Rexulti</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatients 18 to 60 years of age.

          -  Meet DSM-5 criteria for MDE in MDD as determined by the MINI.

          -  Episode duration &gt; 3 months.

          -  Free of psychotropic medications for at least 5 half-lives (e.g. 1 week for most
             antidepressants, 5 weeks for fluoxetine) before baseline Visit 1.

          -  MADRS score ≥ 24.

          -  Fluency in English, sufficient to complete the interviews and self-report
             questionnaires.

        Exclusion Criteria:

          -  Any diagnosis, other than MDD, that is considered the primary diagnosis.

          -  Bipolar I or Bipolar-II diagnosis.

          -  Presence of a significant Axis II diagnosis (borderline, antisocial).

          -  High suicidal risk, defined by clinician judgment.

          -  Substance dependence/abuse in the past 6 months.

          -  Presence of significant neurological disorders, head trauma, or other unstable medical
             conditions.

          -  Pregnant or breastfeeding.

          -  Failure of 4 or more adequate pharmacologic interventions (as determined by the
             Antidepressant Treatment History Form).

          -  Started psychological treatment within the past 3 months with the intent of continuing
             treatment.

          -  Patients who have previously failed escitalopram or showed intolerance to escitalopram
             or brexpiprazole, and patients at risk for hypomanic switch (i.e. with a history of
             antidepressant induced hypomania).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sidney H Kennedy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, St. Michael's University, University of Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Franca M Placenza, PhD</last_name>
    <phone>4166035800</phone>
    <phone_ext>8839</phone_ext>
    <email>franca.placenza@uhn.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Stone</last_name>
      <phone>403-210-8650</phone>
      <email>rnstone@ucalgary.ca</email>
    </contact>
    <investigator>
      <last_name>Glenda M MacQueen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T2A1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Evans</last_name>
      <phone>604-822-8012</phone>
      <email>vanessa.evans@ubc.ca</email>
    </contact>
    <investigator>
      <last_name>Raymond W Lam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8P3B6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Lukas</last_name>
      <phone>905-522-1155</phone>
      <phone_ext>39178</phone_ext>
      <email>plukus@stjosham.on.ca</email>
    </contact>
    <investigator>
      <last_name>Benicio N Frey, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen's University</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L4X3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evan Forth</last_name>
      <email>14ef19@queensu.ca</email>
    </contact>
    <investigator>
      <last_name>Roumen Milev, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franca M Placenza, PhD</last_name>
      <phone>416-603-5800</phone>
      <phone_ext>8839</phone_ext>
      <email>franca.placenza@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Sidney H Kennedy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for Addiction and Mental Health</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6J1H4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ilona Gorbovskaya</last_name>
      <phone>416-535-8501</phone>
      <phone_ext>30231</phone_ext>
      <email>Ilona.Gorbovskaya@camh.ca</email>
    </contact>
    <investigator>
      <last_name>Daniel J Mueller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.canbind.ca</url>
    <description>CAN-BIND study website</description>
  </link>
  <link>
    <url>http://www.macleans.ca/society/how-ai-is-helping-to-predict-and-prevent-suicides/</url>
    <description>Maclean's news article on suicide prediction and CAN-BIND research</description>
  </link>
  <reference>
    <citation>Lam RW, Milev R, Rotzinger S, Andreazza AC, Blier P, Brenner C, Daskalakis ZJ, Dharsee M, Downar J, Evans KR, Farzan F, Foster JA, Frey BN, Geraci J, Giacobbe P, Feilotter HE, Hall GB, Harkness KL, Hassel S, Ismail Z, Leri F, Liotti M, MacQueen GM, McAndrews MP, Minuzzi L, Müller DJ, Parikh SV, Placenza FM, Quilty LC, Ravindran AV, Salomons TV, Soares CN, Strother SC, Turecki G, Vaccarino AL, Vila-Rodriguez F, Kennedy SH; CAN-BIND Investigator Team. Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort. BMC Psychiatry. 2016 Apr 16;16:105. doi: 10.1186/s12888-016-0785-x.</citation>
    <PMID>27084692</PMID>
  </reference>
  <reference>
    <citation>Kennedy SH, Lam RW, Rotzinger S, Milev RV, Blier P, Downar J, Evans KR, Farzan F, Foster JA, Frey BN, Giacobbe P, Hall GB, Harkness KL, Hassel S, Ismail Z, Leri F, McInerney S, MacQueen GM, Minuzzi L, Müller DJ, Parikh SV, Placenza FM, Quilty LC, Ravindran AV, Sassi RB, Soares CN, Strother SC, Turecki G, Vaccarino AL, Vila-Rodriguez F, Yu J, Uher R; CAN-BIND Investigator Team. Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder: A CAN-BIND-1 Report. J Clin Psychiatry. 2019 Feb 5;80(2). pii: 18m12202. doi: 10.4088/JCP.18m12202.</citation>
    <PMID>30840787</PMID>
  </reference>
  <reference>
    <citation>Kennedy SH, Downar J, Evans KR, Feilotter H, Lam RW, MacQueen GM, Milev R, Parikh SV, Rotzinger S, Soares C. The Canadian Biomarker Integration Network in Depression (CAN-BIND): advances in response prediction. Curr Pharm Des. 2012;18(36):5976-89.</citation>
    <PMID>22681173</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 11, 2019</study_first_submitted>
  <study_first_submitted_qc>November 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2019</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Health Network, Toronto</investigator_affiliation>
    <investigator_full_name>Sidney Kennedy</investigator_full_name>
    <investigator_title>Professor of Psychiatry, University of Toronto, Arthur Sommer Rotenberg Chair in Suicide &amp; Depression Studies, St. Michael's Hospital, Principal Investigator, Canadian Biomarker Integration Network for Depression, University Health Network</investigator_title>
  </responsible_party>
  <keyword>major depression</keyword>
  <keyword>major depressive disorder</keyword>
  <keyword>MDD</keyword>
  <keyword>escitalopram</keyword>
  <keyword>brexpiprazole</keyword>
  <keyword>neuroimaging</keyword>
  <keyword>genomics</keyword>
  <keyword>proteomics</keyword>
  <keyword>metabolomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Brexpiprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>This study is funded by the Ontario Brain Institute (OBI). Data collected from this study is entered into a research database called &quot;Brain-CODE&quot;, deployed at a High Performance Computer Virtual Lab (HPCVL). The HPCVL supports the regulatory-compliant (e.g. 21 CRF Part 11, HIPPA, PIPEDA) processes for securing privacy of healthcare data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

